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Focal Therapy Will Become a
Standard Option for Selected Men
With Localized Prostate Cancer
TOTHEEDITOR:Giannarini et al1 provide a fairly vigorous case to
preserve the status quo for men diagnosed with localized prostate
cancer that are contemplating therapy. We saw similar pleas by the
mastectomy proponents when radical mastectomy was being chal-
lengedby lumpectomy.2More recently, similar argumentsweremade
when partial nephrectomy was being proposed as a more suitable
alternative for many.3 It is interesting to reflect, despite the early
protestations, which approach (whole organ v tissue preserving) is
now considered the practice standard for the majority of eligible pa-
tients; in the case of renal cancer without level 1 evidence. Prostate
cancer is the last solid organ cancer in which therapy is directed to the
total extent of the tissue. The key revolutions in breast and kidney care
came about through developments in imaging (mammography and
computed tomography scanning, respectively) that accurately local-
ized the tumor. In prostate cancer, we have relied on a diagnostic
strategy that cannot accurately localize tumors; thedecision to remove
or irradiate a prostate has been a binary one based on the presence or
absence of cancer.
We, and others, believe that the era of accurately depicting loca-
tion in prostate cancer has arrived and with such a paradigm shift the
opportunity of exploiting tumor location4 provides an avenue to
selective therapy that can confer benefit to both patients and health
care systems.
There are a number of reasons why a tissue-preserving approach
should be entertained:
First, there is little to lose. If maximal therapy (radical prostatec-
tomy) failed to confer any significant survival benefits over observa-
tion in the latest study,5 it is unlikely that we are going to see any
differences in survival between two types of therapy—whole gland
and tissue preserving.
Second,weneed todo somethingdifferent.Changingourmeans
of access through expensive capital investments into robotic-assisted
surgerybut doing the sameoperationhasnot improvedoutcomesbut
has certainly increased costs.6
Third, there is plenty of tissue to be preserved. The mean cancer
volume at diagnosis varies between 1-2 cm3 depending on the inten-
sity of screening.7 Most prostates are around 40 cm3 in volume. Even
with the application of amargin it should be possible to preserve well
over half the prostate in the majority of eligible patients.
Fourth, preserving prostate matters. Two registered, prospective
trials have shown that the majority of men (95%) treated in a tissue-
preserving manner are indistinguishable from their status before the
intervention.8 This compares with 20%men preserving erectile func-
tion and 80%urinary continence 2 years after radical treatment when
similar instruments were used in a formal trial setting to elicit func-
tional status.5
Fifth, the diagnostic pathway is changing. In many centers around
theworld the response to an elevatedprostate-specific antigen level is not
abiopsy,but imaging inthe formofmultiparametricmagnetic resonance
imaging to derive location. The information on location will be used to
informa targetedbiopsy.4 If the entireprostateneednotbe sampledmen
will askwhy their entire prostate needs to be subjected to therapy.
Sixth, our understandingof disease is changing. There is growing
evidence thatGleasonpattern 3 represents a phenotype that is incapa-
ble ofmetastatic spread.9We and others have suggested that it should
be redesignated as a noncancer.10 It follows that most secondary le-
sions within the prostate—and they do exist asmostmen have two to
three cancers at diagnosis—are of nomalignant potential. Therefore,
the worry of leaving cancer behind echoes the pleas of the mastecto-
mists that have, with time, proven to be spurious.
Finally, Giannarini et al1 state no conflicts of interest. We, as
surgeons, are all conflicted.Todedicateoneself to a technique through
arduous training makes it hard to give up. Most of us make a living
from these procedures and gain professional esteem fromour activity
throughgrants, publications, and lectures.Whatwedoneed todo is to
listen to patients and the utilities they place on preserving genitouri-
nary function and also in what they require in terms of cancer-related
risk reduction. There is strong evidence that we are not serving their
needs particularly well at present.5 A rapid, but critical phased devel-
opment program of this new technology is what is required in which
we pool resources to create as many opportunities for patients to get
into as many trials or registries as possible.8
Things can and do change quickly. Breast surgeons performing
mastectomy, urologists performing nephrectomy, and vascular sur-
geons performing open aneurysm repairs have all changed. Not
changing in our management of prostate cancer is not an option.
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